Blesin

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Blesin

What is Blesin? Defining the Medicine's Identity

Property Description
Active ingredient Diclofenac (as sodium or potassium salt)
Form Tablets, capsules, topical gels, and injections
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
General purpose Symptomatic relief of pain and inflammation
Origin Synthetic, Phenylacetic acid derivative

What Type of Medicine is Blesin and What is Its Composition?

Blesin is the trade name for a synthetic medicinal product whose active component is Diclofenac, which is officially categorized as a Nonsteroidal Anti-inflammatory Drug (NSAID). This classification places Blesin in a pharmacological group whose primary function is to address pain, inflammation, and fever. Diclofenac is structurally recognized as a benzene-acetic acid derivative, a chemical characteristic associated with potent properties compared to some older NSAIDs. Diclofenac is categorized as an effective analgesic agent for various acute painful conditions, possessing the capability to reduce pain intensity. The medicine is designed to provide consistent pain-relieving effects. The active component is utilized as a single-active entity, often in salt forms like Diclofenac sodium or Diclofenac potassium, meaning its therapeutic effects stem exclusively from this one compound.

Available Forms and General Therapeutic Purpose

Blesin is manufactured in multiple pharmaceutical forms to facilitate various administration needs, often presenting a wider range of options compared to single-form agents. These forms include conventional oral tablets and capsules, as well as topical applications such as gels and creams for localized relief, making it a versatile compound. The general purpose of this medicine is to provide symptomatic relief by mitigating the body's responses of discomfort and swelling, commonly used, for instance, in the management of acute flare-ups of discomfort. Its function is achieved by interrupting the synthesis of prostaglandins, which are critical chemical compounds that act as mediators of pain and inflammation in the body. The primary action of Diclofenac is reducing inflammation and swelling by controlling the biological cascade that causes them. This emphasizes that the medicine is suited for addressing both the pain and the underlying physical swelling. By controlling these key physiological messengers, Blesin offers a broad therapeutic benefit in managing localized and generalized symptoms of inflammatory irritation.

Regulatory References

  1. Diclofenac - StatPearls (NIH)

What side effects are possible with Blesin?

Possible side effects and safety information

The safety profile for Blesin, whose active substance is Diclofenac, is formally defined by government regulatory agencies through classifications of frequency, affected body system, and severity. The most frequently observed reactions are classified as Common, occurring in up to 10 out of 100 users, and primarily involve the Gastrointestinal System (e.g., nausea, dyspepsia, abdominal pain, diarrhoea) and the Nervous System (headache, dizziness). Elevated liver enzymes are also commonly reported in regulatory documents.

Serious Adverse Reactions

Regulatory warnings emphasize the potential for serious events, often referred to as Serious Adverse Reactions, which are highlighted due to their clinical significance, even if they are documented as Rare or Uncommon. These include life-threatening events such as serious gastrointestinal bleeding, ulceration, and perforation, which can occur at any time during treatment.

Furthermore, the medicine is associated with a risk of serious cardiovascular thrombotic events (e.g., myocardial infarction and stroke). This risk is officially noted to increase with higher doses and longer duration of use, establishing an exposure-related safety pattern.

Population-Specific Constraints

The official labeling outlines specific constraints for certain populations. The medicine is contraindicated for patients with established congestive heart failure (NYHA Class II-IV) or other existing cardiovascular disease. It is also contraindicated during the third trimester of pregnancy and in patients with active or recurrent gastrointestinal ulceration or bleeding. Older adults are specifically noted in regulatory documents as having a greater risk for severe gastrointestinal complications.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage with Blesin (diclofenac) may present with documented systemic manifestations often involving the gastrointestinal and central nervous systems. Officially listed initial signs include nausea, vomiting, epigastric pain, and CNS effects such as drowsiness, dizziness, headache, and tinnitus. However, regulatory documents stress that overdose can progress to severe outcomes. These include acute renal failure, hepatic dysfunction, gastrointestinal bleeding, hypertension, and severe neurological events like seizures or coma in very severe cases. Elderly patients are officially noted as being at greater risk for serious gastrointestinal events.

Mandated Emergency Intervention

It is officially required to seek immediate medical help and contact a Poison Control Center for any suspected overdose. The regulatory management approach is defined as symptomatic and supportive care, as no specific antidote is known for this overdose. In cases of large ingestion, specific procedures like the administration of activated charcoal and gastric lavage may be considered. Continuous hospital monitoring is mandated to assess for signs of organ damage, including internal bleeding and kidney injury, often requiring blood, urine, or ECG testing.

Therapeutic Uses of Blesin

What Blesin treats: Main Uses and Benefits

The therapeutic benefit of Blesin is directed toward managing symptoms related to inflammatory or irritative states that often create noticeable physiological strain. The medication is commonly used across conditions presenting with acute, recurrent, or chronic episodes of pain and swelling. The medication is indicated for supportive relief across several conditions, from chronic states to acute symptomatic events.

This medicine is applied across domains where additional symptomatic support is needed, assisting with relief in conditions like Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis, acute sprains and strains, post-operative discomfort, migraine attacks, and primary dysmenorrhea.

Chronic Inflammatory Joint Pain and Stiffness

This medicine is applied across domains where additional symptomatic support is needed in conditions involving episodic or fluctuating manifestations. It is relevant for managing symptom clusters that may become intense or disruptive, providing support that helps improve day-to-day comfort during periods of heightened symptoms associated with persistent joint pain and physical stiffness.


Quick Fact: Supportive Relief for Inflammatory Joint Pain

Acute Musculoskeletal Injury and Episodic Pain

Blesin is relevant when supportive symptom management is appropriate in scenarios where symptoms may intensify temporarily, such as pain following surgical procedures or trauma. It may assist with managing symptoms that interfere with daily functioning in situations where patients experience localized swelling and discomfort, contributing to improved comfort during periods of heightened symptoms, including acute migraine attacks and primary dysmenorrhea.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Blesin (Diclofenac) is defined by official regulatory bodies as contraindicated for several patient populations, meaning its use is strictly prohibited.

Contraindicated Populations

Classification Population/Condition
Cardiovascular Risk Established Congestive Heart Failure (NYHA Class II–IV), Ischemic Heart Disease, or use in the setting of Coronary Artery Bypass Graft (CABG) surgery.
Gastrointestinal Risk Active gastric or intestinal ulceration, bleeding, or perforation, or a history of recurrent peptic ulcer/haemorrhage.
Organ Failure Severe hepatic failure or severe renal failure.
Allergy Known hypersensitivity to diclofenac or any allergic-type reactions (e.g., asthma, urticaria) precipitated by aspirin or other NSAIDs.

Age and Pregnancy Eligibility

Use is not recommended in the last trimester of pregnancy (after approx 30 weeks gestation). Most oral formulations are not established as safe or effective for children below 12 to 14 years of age. Use in elderly patients requires particular caution and close monitoring due to an increased risk of serious adverse reactions, as specified in regulatory labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes the officially documented interaction patterns of Blesin (Diclofenac) as stated in government regulatory labeling.

Documented Combination Restrictions

Blesin is contraindicated for the management of peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery. Co-administration with other systemic Nonsteroidal Anti-inflammatory Drugs (NSAIDs) or analgesic doses of aspirin is generally not recommended or contraindicated due to the additive risk of gastrointestinal adverse events.

Pharmacodynamic and Risk Interactions

Co-administration with Anticoagulants (e.g., Warfarin), Antiplatelet agents, and Selective Serotonin Reuptake Inhibitors (SSRIs) is documented to significantly increase the risk of hemorrhage, particularly gastrointestinal bleeding. Diclofenac may also reduce the antihypertensive effect of co-administered medicines such as ACE Inhibitors and Angiotensin Receptor Blockers (ARBs).

Exposure-Modifying Interactions

Diclofenac exposure can be increased by medicines classified as strong CYP2C9 inhibitors; for example, Voriconazole is officially documented to increase Diclofenac plasma concentration (AUC/Cmax). Conversely, Diclofenac may increase the serum concentrations and toxicity risk of other medicines due to reduced clearance, specifically documented for Lithium and Methotrexate.

Non-Medicinal Substance Interactions

Consumption of alcohol is officially noted to increase the risk of gastrointestinal bleeding. Additionally, for specific oral formulations, taking Blesin with food may lead to reduced effectiveness.

Mechanism of Action

Inhibition of the Cyclooxygenase Enzyme System

The drug's core mechanism involves the competitive inhibition of the Cyclooxygenase (COX) enzymes, targeting both the constitutive COX-1 and inducible COX-2 isoforms with preferential affinity for COX-2. This molecular blockade prevents the conversion of the fatty acid arachidonic acid into the prostanoid precursors, which function as key physiological mediators.

Modulation of Prostaglandin Synthesis Pathways

By suppressing COX activity, the drug reduces the synthesis of key chemical messengers, primarily prostaglandin E2 ( PGE2), at the site of tissue irritation. This chemical pathway interruption suppresses the PGE2 signal that normally sensitizes peripheral nerve endings and triggers blood vessel changes.

Reduction of Prostaglandin-Mediated Signal Transduction

The functional consequence of this mechanism is the reduction of prostaglandin-mediated signal transduction across peripheral and central systems. The reduction of PGE2 influences local vascular permeability and blood flow, suppressing the extravasation of fluid. This action also supports the modulation of hypothalamic temperature control, resulting in decreased nerve excitability and reduced core temperature.

Dosage and Administration Information

How to Use Blesin

The usage of Blesin involves specific patterns for administration across multiple forms and routes. The medicine is utilized for administration via Oral, Topical, and Parenteral (Intramuscular or Intravenous) routes, depending on the specific formulation.

Dosing and Administration Patterns

Dosage ranges vary based on the specific formulation and the condition being addressed. For chronic conditions such as arthritis, the total daily oral dosage typically ranges from 100 mg to 200 mg, often taken in divided doses throughout the day. Extended-release forms, however, are generally utilized for once-daily use, such as 100 mg. The drug is intended for administration using the lowest effective dose for the shortest duration necessary.

Preparation and Handling

The consumption of oral forms involves adherence to specific timing. Delayed-release (DR) and Extended-release (ER) tablets are generally taken with or immediately following a meal. Conversely, specialized forms like the powder for oral solution or liquid-filled capsules are taken on an empty stomach for proper absorption. Furthermore, the administration of DR and ER tablets requires that they be swallowed whole and not be crushed, split, or chewed, as this maintains the intended release mechanism. Different salt forms and release types are not considered therapeutically interchangeable.

Population-Specific Use

Dose adjustments for certain patient populations are standard for this medication. In older adults, treatment is typically initiated at the lower end of the recommended range. While patients with mild to moderate renal impairment may not require a specific adjustment, hepatic impairment may necessitate a dose reduction.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Blesin

Evidence for Use in Chronic Inflammatory Joint Conditions

The research base for Blesin in conditions characterized by fluctuating or episodic manifestations like Osteoarthritis (OA), Rheumatoid Arthritis (RA), and Ankylosing Spondylitis (AS), is significantly structured around short-term Randomized Controlled Trials (RCTs). These studies were conducted during periods of increased symptom activity and often involved adults and older adults. Researchers were examining outcomes related to physical discomfort and daily functioning or activity level over defined time intervals.

For OA, studies explored patient-reported outcomes describing perceived discomfort and physical function. Studies report measurements where the patterns of reported pain levels were not the same as those recorded by individuals taking an inactive substance (placebo) over short follow-up periods. In RA and AS, research focused on symptomatic outcomes such as joint pain and stiffness. The evidence provides insight into short-term changes in pain and function, but data for certain long-term structural outcomes remain insufficient.


Evidence for Use in Acute Pain and Symptomatic Events

Blesin was studied for its use in acute conditions associated with disruptive episodes, such as post-operative pain, musculoskeletal injuries, primary dysmenorrhea, and migraine attacks. The research used very short-term, single-dose RCTs, applied in studies examining symptom intensity or variability. Findings consistently described patterns related to the speed of symptom change and the highest level of symptomatic difference measured in the immediate post-dosing period. The results apply only to the immediate, short-term management of the acute episode, and research exploring the transition of these acute symptoms into chronic problems is not well characterized.


What is Still Uncertain About Blesin Research

Research provides context but not individual predictions. A major uncertainty is that long-term effects are not fully established; evidence for symptomatic durability beyond six months is primarily derived from observational data, which can have inherent limitations. Furthermore, comparative evidence is lacking in some areas, particularly concerning the direct research comparison between Blesin and the newest therapeutic options for chronic conditions. These limitations mean that findings describe group patterns, not personal outcomes, and reflect the specific conditions under which the studies were conducted.

Key Studies & References

  1. Diclofenac - StatPearls [Internet]
  2. Diclofenac Oral: MedlinePlus Drug Information

Frequently Asked Questions (FAQ)

Common questions about Blesin (FAQ)


Q: Is Blesin a type of antibiotic or steroid?

According to official product information, Blesin is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). It is used to relieve pain and inflammation. It is neither an antibiotic, which is used to fight bacterial infections, nor a steroid, which is a type of hormone-based anti-inflammatory medicine.

Q: How quickly should someone start to notice an effect from Blesin?

Studies describe that the active ingredient is absorbed with speed characteristics noted in regulatory documents. For acute pain, research has looked at the speed of symptomatic change shortly after administration. For chronic conditions like arthritis, the effects are often assessed in studies after a period of consistent use.

Q: Is the full benefit of Blesin seen right away, or does it build up over time?

For immediate symptoms, such as acute pain, effects are often observed shortly after dosing. For chronic inflammatory conditions, the drug's effects are often assessed in studies after a period of consistent use. Researchers usually assess the drug's effects after consistent use has been maintained for a specific time period.

Q: Can Blesin cause mood swings or changes in sleep patterns?

Official labeling for Blesin's active ingredient notes that adverse events affecting the Nervous System have been documented. While common reports include dizziness and headache, less common experiences such as drowsiness, insomnia, and dream abnormalities have also been reported in official documents.

Q: Should a person drive or operate machinery while using Blesin?

Official product information contains warnings regarding driving or operating machinery. This is because possible central nervous system effects, such as dizziness, drowsiness, or visual disturbances, have been documented, which could affect a person’s ability to perform these tasks safely.

Q: What are the long-term effects of using Blesin?

Official warnings note that the documented risk of serious adverse events, such as cardiovascular and gastrointestinal complications, is described as increasing with higher doses and longer duration of use. These are considered exposure-related safety patterns.

Q: Why do doctors prescribe Blesin instead of similar, older medicines?

Official classification defines the active ingredient in Blesin as a potent Nonsteroidal Anti-inflammatory Drug (NSAID) used to provide symptomatic relief of pain and inflammation. Research evidence describes the active ingredient as an established, potent analgesic agent for various painful conditions.

Q: Is Blesin approved for use in children?

The official product information states that most oral forms of Blesin are not established as safe or effective for children below 12 to 14 years of age. Some regulatory bodies have approved specific formulations for use in children above 14 years old.

Q: Does taking Blesin affect the results of common lab tests?

Official labeling mentions that Blesin use has been associated with changes in lab tests, most commonly elevated liver enzymes (e.g., transaminases). For this reason, official monitoring of liver and kidney function is often recommended for patients receiving long-term treatment.

Q: Is Blesin treatment a short course or a long-term commitment?

Consistent with regulatory documentation for the drug class, administration is described as involving the lowest effective dose for the shortest duration required to control symptoms. Treatment duration depends on the specific condition being addressed.

Q: Can Blesin cause allergic reactions, and what are the signs?

Official documents list allergic-type reactions, including severe skin reactions and anaphylaxis, as possible adverse events. Official warnings advise seeking immediate medical attention if signs of a severe allergic reaction, such as swelling, hives, or difficulty breathing, occur.

Q: Can I stop taking Blesin abruptly, or do I need to taper off?

Official product documentation for the active ingredient does not specify a tapering schedule or describe withdrawal symptoms. Blesin is primarily used for symptomatic relief, and the decision to start or stop treatment is a matter of clinical judgment related to the patient’s underlying condition.

Q: Is Blesin considered habit-forming or addictive?

The active ingredient in Blesin is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID) and is not a scheduled controlled substance. It is not associated with the patterns of physical dependence seen with controlled medications.

Q: Does Blesin interact with common medications for anxiety or depression?

Official documents describe that taking Blesin with Selective Serotonin Reuptake Inhibitors (SSRIs) may increase the risk of serious bleeding, particularly in the gastrointestinal tract. Information regarding use with other classes of drugs for these conditions is best sought from a healthcare professional.

Q: Are the side effects of Blesin permanent?

Most documented side effects are typically reversible once the medicine is stopped. However, serious adverse events, such as severe gastrointestinal damage or cardiovascular thrombotic events, are noted in regulatory warnings as outcomes that may result in permanent clinical consequences.

Q: Does Blesin interact with herbal supplements like St. John's wort?

The drug is metabolized by specific liver enzymes, including CYP2C9. Regulatory information notes that strong inhibitors or inducers of these enzymes, which may include certain herbal supplements, can change the concentration of Blesin in the body. Changes to drug concentration may require assessment by a healthcare provider.

Q: How do studies describe Blesin's overall success rate?

Systematic reviews of research studies have described various measures of success. For example, in research on topical forms for chronic pain, a 'clinical success rate' (defined as a 50% reduction in pain) was achieved in a majority of participants using the drug compared to those taking an inactive substance.

Q: What is the difference between brand-name Blesin and a generic version?

Generic versions are required by regulatory bodies to be bioequivalent to the brand-name product. This means they must deliver the same amount of the active ingredient into the bloodstream in the same amount of time. Differences usually relate only to inactive ingredients or the physical form of the tablet/capsule.

Q: Is it normal to feel a certain way when first starting Blesin?

When starting treatment, it is common to experience side effects described in official documents, such as gastrointestinal symptoms (nausea, abdominal pain) or nervous system symptoms (headache, dizziness). These are considered commonly reported effects.

Q: How long does Blesin stay in the system after the last dose?

Official pharmacokinetic data indicates that the terminal half-life of the unchanged active ingredient in the bloodstream is approximately 2 hours. This means the body processes the drug relatively quickly, though metabolites may remain in the system longer.

Q: Does Blesin have a risk of causing weight gain or loss?

Official product information for the active ingredient lists weight changes (both gain and loss) as an additional adverse experience that has been reported occasionally.

Q: Is Blesin related to any substance that is often misused?

The active ingredient in Blesin is a Nonsteroidal Anti-inflammatory Drug (NSAID) and is not classified as an opioid or narcotic. It is not subject to the special regulatory controls designated for substances associated with a risk of misuse.

Q: Is Blesin's use described differently in international guidelines?

The core mechanism and classification of the drug remain consistent globally. However, international regulatory bodies (such as those in Europe and the UK) have sometimes issued unique or updated warnings, particularly concerning cardiovascular risk, which may influence local prescribing guidance.

Q: Can Blesin affect fertility or sexual function?

Official product information notes that, similar to other medicines that inhibit prostaglandin synthesis, the active ingredient may temporarily impair female fertility. This effect is described as reversible upon stopping the medicine.

Q: Are there specific patient groups that respond better to Blesin?

Clinical studies describe patterns of efficacy for groups of patients with specific conditions, such as osteoarthritis or acute pain. Official documents do not contain definitive claims that one patient group responds 'better' than another, but rather reflect general effects across the studied populations.

Q: Are there specific official monitoring requirements while taking Blesin?

Official regulatory documentation recommends that patients receiving long-term treatment undergo laboratory monitoring. This monitoring includes checking measurements of transaminases (liver enzymes) and kidney function to help detect potential severe adverse events.

Q: Are there special considerations for individuals who have diabetes and use Blesin?

Official warnings indicate that treatment requires consideration when used by patients with significant cardiovascular risk factors, which includes diabetes mellitus. Additionally, co-administration with certain diabetes medicines may require more frequent blood sugar monitoring.

Q: Are there any special considerations for people with certain genetic conditions taking Blesin?

The drug is primarily metabolized by the liver enzyme CYP2C9. Regulatory information indicates that individuals with genetic variations that reduce the function of this enzyme may have significantly higher levels of the drug in their body, which may be assessed by a healthcare provider.

How should Blesin be stored and disposed of?

Storage Requirements

Blesin (diclofenac) must be stored properly to maintain its potency. Most oral tablet and topical forms should be stored at room temperature, typically below 30 C (86F), in a closed container, away from excessive heat.

The medication must be kept in the original container and protected from moisture and direct light.

It is explicitly instructed to Keep from freezing, especially for topical gels and liquid formulations.

Disposal Instructions

All expired or unused Blesin must be properly disposed of. The best option is to use an official drug take-back program or mail-back service.

If a take-back program is not available, the medicine should be removed from its container, mixed with an undesirable substance (such as dirt or coffee grounds), sealed in a bag or container, and placed in the household trash. Do not flush the medicine down the sink or toilet unless the official drug labeling specifically instructs you to do so.

Keep the medicine out of the reach of children and pets during storage and disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Blesin found in:

A-Z Index: